/ /

  • linkedin
  • Increase Font
  • Sharebar

    B + L places focus on innovation in pharma, surgical, vision care

     

    New glaucoma drug

    The single most exciting development project is latanoprostene bunod (LBN, Vyzulta), a prostaglandin analogue that acts as a nitric oxide donor. The agent has two mechanisms of action, the familiar latanoprost effect of increasing uveoscleral outflow, with nitric oxide donation acting to increase outflow through the trabecular meshwork.

    Two recent phase III studies found that LBN provided a mean reduction in IOP of 7.5-9.1 mm Hg over 3 months of treatment, a result that was statistically superior to timolol between 2 and 12 weeks. There were no significant safety findings from either trial.

    “We are excited to be working on an investigational product that provides two mechanisms of action to deal with elevated ocular pressure,” Valorie said. “We are looking forward to the potential and the possibility for this agent to serve both patients and physicians in the future.”

    Fred Gebhart
    The author is a correspondent for Urology Times, a sister publication.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results